Kyowa Kirin Poteligeo MINT study shows 62.4% response in cutaneous T-cell lymphoma
Final results from Germany's 109-patient MINT study show a 62.4% best overall response rate and median time to next treatment of 14.9 months with Poteligeo. The findings support its established role in cutaneous T-cell lymphoma while highlighting meaningful toxicity, concurrent treatment and observational-study limitations.
